ReviewJournal for immunotherapy of cancer2019
Pericardial effusion under nivolumab: case-reports and review of the literature.
Review in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.Cancer immunology, immunotherapy : CII · 2021Pooled it
- A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.Journal of thoracic disease · 2026Review
- Pembrolizumab-Associated Polyserositis with Eosinophilic Pleural Effusion During Adjuvant Therapy for Clear Cell Renal Cell Carcinoma: A Case Report and Targeted Review.Current oncology (Toronto, Ont.) · 2026Review
- Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact.Cardiovascular toxicology · 2026Review
- Unraveling Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities: Pathway Insights, Mechanisms, and Emerging Therapeutic Targets.Reviews in cardiovascular medicine · 2026Review
- Life-threatening immune-related adverse events in the intensive care unit: a narrative review.Intensive care medicine · 2025Review
- Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.BMC pharmacology & toxicology · 2025Article
- Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).Scientific reports · 2024Article
- Pericardial effusion in oncological patients: current knowledge and principles of management.Cardio-oncology (London, England) · 2024Review
- Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Article
- Article
- Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis.Current oncology reports · 2023Review
- Pembrolizumab induced pericardial tamponade: A case report.Clinical case reports · 2023Article
- Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database.Clinical drug investigation · 2023Article
- Advances in immune checkpoint inhibitors induced-cardiotoxicity.Frontiers in immunology · 2023Review
- Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects.Oncology reviews · 2023Review
- Checkpoint-inhibitor induced Polyserositis with Edema.Cancer immunology, immunotherapy : CII · 2022Article
- Myocarditis Induced by Immunotherapy in Metastatic Melanoma-Review of Literature and Current Guidelines.Journal of clinical medicine · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under immunotherapies. Cardiotoxic side effects, initially thought to be rare, are more often encountered paralleling the expanding use of immune checkpoint blockade. Among them, pericardial effusion and tamponade deserve attention as they may present with unusual symptomatology. CASE PRESENTATION: We report three cases of pericardial effusion under nivolumab for lung adenocarcinoma. Two cases of early and late-onset pericardial effusion were symptomatic with tamponade and one case occurred without any symptoms. Pericardiocentesis with pericardial biopsy was performed in symptomatic pericardial effusion followed by the administration of a corticotherapy. Pericardial biopsies showed infiltration of T-lymphocytes, mostly CD4
conclusionsWe review the literature on pericardial effusion under nivolumab to further discuss the hallmarks of pericardial effusion under nivolumab and the management of nivolumab therapy in this situation. In conclusion, pericardial effusion as an immune-related adverse event under nivolumab appears less rare than initially thought and may require particular attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.